Azole Antifungals: Physiologically-Based Pharmacokinetic (PBPK) Modeling and Prediction of Drug-drug Interactions (DDIs) - Simulations Plus

Jan 1, 2009

| Poster

Azole Antifungals: Physiologically-Based Pharmacokinetic (PBPK) Modeling and Prediction of Drug-drug Interactions (DDIs)

Fraczkiewicz G, Lukacova V, Parrott N, Bolger MB, Woltosz WS

Keywords: azole antifungals, drug-drug interactions (DDIs), Physiologically based pharmacokinetic (PBPK) modelingSoftware: GastroPlus®Conference: RosenonDivision: Simulations Plus

Purpose

Develop PBPK models for azole antifungals for prediction of DOis.

By Grace Fraczkiewicz, Viera Lukacova, Michael B Bolger, Walt S Woltosz

Click Here to View

Contact Us About This Poster

Similar Resources

Simulations Plus Poster

11/30/2021

Validation of non-compartmental analysis (NCA) and bioequivalence results of PKanalix with respect to Phoenix WinNonLin

Pasquiers B, Gualano V, Twarogowska M, Ayral G

Keywords: bioequivalence, compartmental analysis (CA), drug-drug interactions (DDIs), Food effects, noncompartmental analysis (NCA), pharmacokinetics, pkanalix featureSoftware: MonolixSuite™, Division: Lixoft

Read More Click Here to View

Simulations Plus Webinar

04/27/2021

Human-on-a-Chip combined with PBPK modeling for in vitro/in vivo PK/PD extrapolation

Hickman J, Lukacova V

Keywords: drug-drug interactions (DDIs), gastroplus, Human-on-a-Chip (HoaC) systems, in vitro, PK predictionSoftware: GastroPlus®Division: Simulations Plus

Read More Click Here to View